The hormonal contraception market is set to thrive at a CAGR of 5.2% between 2022 and 2032. The market currently is expected to reach a value of US$ 17.49 Billion in 2022 and is anticipated to achieve a revenue of US$ 29.04 Billion by 2032.
“Adoption of hormonal contraception for birth control, rising awareness about unwanted pregnancy and rapid investments by the major key players are expected to propel the hormonal contraception market.”
| Attributes | Details |
|---|---|
| Hormonal Contraception Market Size (2022E) | US$ 17.49 Billion |
| Hormonal Contraception Projected Size (2032F) | US$ 29.04 Billion |
| Value CAGR (2022 to 2032) | 5.2% |
The use of hormones to prevent pregnancy is becoming mainstream, such as hormonal pills that contain estrogen and progesterone or progesterone. These hormones prevent pregnancy by blocking the release of eggs from the ovaries while thinning the lining of the uterus along with thickening the mucus in the cervix to help keep sperm from integrating with the egg.
The increased population has also fueled the use of contraceptives all around the world. Birth control technology has driven the hormonal contraception market by enabling safety, effectiveness, availability, accessibility, and affordability.
Females use hormonal contraception extensively across the world. This happens due to the increased public awareness of the importance of making informed decisions regarding one's sexual and reproductive health. This is leading to hormonal contraception being increasingly used as a method of birth control.
Other than the reversible methods of birth control, such as intrauterine contraception and copper T, have slowed down the application of hormonal contraception. However, the instant way to stop pregnancy is hormonal contraception. People have started to realize its importance and thus fueling the demand for hormonal contraception.
In contrast to the progestogen-only method, which reduces the frequency of ovulation, the combination treatment suppresses ovulation while thickening cervical mucus. Furthermore, these birth control measures alter the uterus' environment, making it hard to fertilize.
Increased awareness about unwanted pregnancy, changing lifestyles and government support programs have increased the demand for hormonal contraception. Furthermore, the research and development programs are strongly working for the betterment of contraceptive drugs while reducing the side effects.
The endocrine system is a particular class of pregnancy prevention methods called hormonal contraception. This procedure stops ovulation by using a variety of female hormones. In combination forms, such as progestin and estrogen two hormonal contraceptive formulations are available.
However, in the market, there are only two kinds of hormonal contraception. i.e. combination contraceptive hormone and progestin contraceptive. Progesterone or any of its synthetic counterparts are exclusively present in progestogen.
In contrast to the progestogen-only method, which reduces the frequency of ovulation, the combination treatment suppresses ovulation while thickening cervical mucus. Additionally, these birth control methods alter the uterus' environment, making it unfavourable to fertilization.
The major use of hormonal contraception is by women for the prevention of pregnancy. In the process, the intake imbalances the hormones and can cause different complications. The latest development through research and development programs are helping with the side effects of contraception pills.
With the FDA approvals, combined estrogen/progestin contraception help the women with different complications. Most women (83%) have regular menses when using the contraceptive. This advancement helps in reducing bleeding and faster return to fertility than DMPA and this too with lower side effects.
This hormonal contraception includes dosing one patch weekly for three consecutive weeks. The advanced mean serum helps in the reduction of excessive bleeding and infection caused by hormonal contraception. It is generally helpful and effective to the women that have a weight of over 90 Kgs.
Females utilize hormonal contraception extensively across the world. Due to increased public awareness of the importance of making informed decisions regarding one's sexual and reproductive health, hormonal contraception is increasingly used as a method of birth control.
Furthermore, the market is expanding as a result of increasing expenditures by key manufacturers in the R&D of novel contraceptive devices and supportive programs launched by various governments to provide access to contraceptives. The increase in the female population worldwide, urbanization, more awareness of hormonal contraception, and supportive NGOs all contribute to the expansion of the hormonal contraceptive industry.
Furthermore, a rise in emphasis on family planning, health problems related to teenage pregnancies, and an increased understanding of contemporary contraceptive methods are major drivers anticipated to fuel market expansion for hormonal contraceptives globally.
Geographically, the hormonal contraception market is distributed into major seven regions –North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa. Among these regions, the North American region dominates the market due to the presence of the major key players, a high percentage of unintended pregnancies and increasing knowledge of sexual health issues.
Key factors supporting the regional growth of the European market are the advent of innovative contraceptive methods for women and the rapid expansion of the economy.
Additionally, the Asia-Pacific market for hormonal contraception is anticipated to show rapid growth in the forecast period due to the development in the pharmaceutical industry and government involvement to impose some measure of control on the birth rate of the population.
Some of the key manufacturers operating in the hormonal contraception market are Abbvie Inc., Bayer AG, Pfizer Inc, Agile Therapeutics, Pregna International Ltd., Lupin Pharmaceuticals Inc, Janssen Pharmaceuticals Inc., Teva Pharmaceuticals Industries Ltd., Afaxys, Inc., Johnson & Johnson, Merck & Co, Inc, Church & Dwight, Co, Inc and others.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 5.5% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segment Covered | Product, Hormone, End User, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC, South Africa, Israel |
| Key Players | Abbvie Inc.; Bayer AG; Pfizer Inc; Agile Therapeutics; Pregna International Ltd.; Lupin Pharmaceuticals Inc; Janssen Pharmaceuticals Inc.; Teva Pharmaceuticals Industries Ltd.; Afaxys, Inc.; Johnson & Johnson; Merck & Co, Inc; Church & Dwight, Co, Inc |
| Customization | Available Upon Request |
The global hormonal contraception market is anticipated to register a CAGR of 5.5% during the forecast period.
Abbvie Inc., Bayer AG, Pfizer Inc, Agile Therapeutics, Pregna International Ltd., Lupin Pharmaceuticals Inc, Janssen Pharmaceuticals Inc., Teva Pharmaceuticals Industries Ltd., Afaxys, Inc., Johnson & Johnson, Merck & Co, Inc, Church & Dwight, Co, Inc among others are some prominent hormonal contraception market players.
Explore Similar Insights
Hormonal Contraception Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
